06:30 AM EDT, 06/17/2025 (MT Newswires) -- Regeneron Pharmaceuticals ( REGN ) has decided not to raise its $256 million bid for 23andMe, paving the way for co-founder Anne Wojcicki's TTAM Research Institute to regain control of the genetic testing firm through a $305 million offer, Reuters reported on Monday, citing a company spokesperson.

Regeneron previously outbid Wojcicki's earlier $146 million proposal. The company spokesperson said the company will continue genetics-driven research through its platforms.

Regeneron shares were down over 1% in recent premarket activity.

Regeneron did not immediately respond to requests for comment from MT Newswires.

(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)